SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.74-2.1%Dec 17 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (1969)11/6/2000 1:47:42 PM
From: Biomaven  Read Replies (1) of 52153
 
Equivalency can be a tougher issue.

A good example here (although not a biotech product) is Premarin, the near-billion dollar AHP drug extracted from cow urine. Generic competitors were denied "equivalence" because the AHP drug contained what most disinterested observers agreed were extraneous proteins that weren't also in the generic. This has been in dispute for years, so maybe it's been resolved by now.

Another hormone, Synthroid, also put up a huge fight against generics.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News